November/December 2000 · Vol. 2 · No. 6

Subject Index

Abstracts, 2000 Annual Clinical Genetics Meeting, 1
ACMG: *see* American College of Medical Genetics
ACMG/ASHG statement
genetic testing for colon cancer, 362
tandem mass spectrometry in neonatal screening, 267
technical and clinical assessment of fluorescence in situ hybridization: technical considerations, 356
American College of Medical Genetics
2000 Annual Clinical Genetics Meeting, 1
brief history of, 255
College News, 153, 205, 259, 304, 369
future directions in, 255
guidelines, expert witness testimony for the specialty of medical genetics, 367
policy statement
informed consent for medical photographs, 353
universal newborn hearing screening, 149
presentations at medical meetings, colorblindness and (letter), 350
presidential address, 255
recommendations for standards for interpretation of sequence variations, 302
Androgen receptor, women with abnormal X chromosome, 136
Angelman syndrome, interstitial duplications, phenotype correlations for, 131
Asplenia, heterotaxy and, prevalence in newborns, 157
Athletes, female, gender verification for, 249
Autism, interstitial duplications and, 131

Berlin diagnostic criteria, Marfan syndrome, dural ectasia in, comparison with Ghent criteria, 278
Biochemical genetics, diagnosis and management of genetic disease and, 328
***BRCA1* mutation test,** negative result, mammography behavior after, 307
Breast cancer, mammography behavior after negative *BRCA1* mutation test result and, 307

Cancer: *see also* specific type
genetic testing validation and (editorial), 155
Cardiovascular malformations, heterotaxy and, prevalence in newborns, 157
CFTR gene, cystic fibrosis and, interactivity between, 124
CGG repeat dynamics, fragile X syndrome, similarity in siblings, comparison with unrelated patients, 242
Chorionic villus sampling, malformations in children exposed to (letter), 300
Chromosome 3q, optic atrophy and, clinical heterogeneity of, 283
CLN gene, late-infantile neuronal ceroid lipofuscinosis, heterogeneity of, 312
Colorblindness, presentations at medical meetings and (letter), 350
Colorectal cancer, genetic testing for, ACMG/ASHG statement, 362
Commentaries
Challenges in communicating genetics: A public health approach, 198
Some ethical implications of the Human Genome Project, 193
Computed tomography, Marfan syndrome, dural ectasia in, 173
Congenital anomalies
glycosylation disorders, prevalence and pathogenesis, 329
women with abnormal X chromosome and, 136
Congenital heart defects, heterotaxy and, prevalence in newborns, 157
Coronary heart disease, genetic testing validation and (editorial), 155
C282Y mutation, HFE genotypes contribution to iron overload disease and, 271
Cystic fibrosis
CFTR gene and, interactivity between, 124
psychological effects and reproductive uncertainty in (letter), 203

Deafness, universal newborn screening and, ACMG policy statement, 149
Depression, interstitial duplications and, 131
Developmental delay, global, interstitial duplications and, 131
Diabetes
genetic testing validation and (editorial), 155
maternal, heterotaxy and, prevalence in newborns, 157
Duplication, interstitial, characteristics, 131
Dural ectasia, in Marfan syndrome
Berlin vs. Ghent diagnostic criteria, 278
MR and CT findings and criteria, 173
Dyspraxia, verbal, in galactosemia, outcomes analysis, 142

Editorials
Clinical validation of genetic tests, 155
From the Editor's desk, 123
Lessons from genetic discrimination, 207
Education, genetics, health professionals and, 226
Environmental effects, genetic discrimination and (editorial), 207
Epidemiology
CFTR gene and cystic fibrosis interactivity, 124
congenital glycosylation disorders, prevalence and pathogenesis, 329
genetic testing, population-based registry use in validation of, 186
heterotaxy, associated conditions and prevalence in newborns, 157
osteoporosis, familial risk profile for, 222
Ethical issues
gender verification of female athletes, 249
Human Genome Project, ethical implications of (commentary), 193

Familial clustering, fragile X syndrome, similarity in siblings, comparison with unrelated patients, 242
Familial studies: *see also* Genetic studies/counseling
family history-taking in family practice, 180
osteoporosis, familial risk profile for, 222
Fatty acid transport disorders, metabolic evaluation, 338
Fetal screening, chorionic villus sampling, malformations in children exposed to (letter), 300
Fluorescence in situ hybridization, technical and clinical assessment of, ACMG/ASHG statement, 356
Folic acid, neural tube defect prevention, college women's awareness and consumption of, 209
Fragile X syndrome, similarity in siblings, comparison with unrelated patients, 242

Galactosemia, verbal dyspraxia in, outcomes analysis, 142
Gender verification, female athletes and, 249
Genetic discrimination
(editorial), 207
by health insurers, patient fear of, legal protections and, 214
Genetic disease, biochemical genetics role in diagnosis and management, 328
Genetic services/counseling
family history-taking in family practice, 180
osteoporosis, familial risk profile for, 222
Genetic studies/testing
clinical validation of (editorial), 155
family history-taking in family practice and, 180
fragile X syndrome, similarity in siblings, comparison with unrelated patients, 242
genetic testing for colon cancer, ACMG/ASHG statement, 362
inborn errors of metabolism, molecular diagnosis of, 345
mammography behavior after negative *BRCA1* mutation test result and, 307
Paget disease of bone and limb-girdle muscular dystrophy, clinical and molecular studies in family with, 232
population-based registry use in validation of, 186
sequence variation interpretation, ACMG recommendations for standards for, 302
Genetics
CFTR gene and cystic fibrosis interactivity, 124
expert witness testimony, ACMG guidelines, 367
Internet resources and (letter), 351
public communication of findings in (commentary), 198
Genetics education
health professionals and, 226
resources on the Internet, 296
Genetics in Medicine, report on journal (editorial), 123
Ghent diagnostic criteria, Marfan syndrome, dural ectasia in, comparison with Berlin criteria, 278
Global, interstitial duplications and, 131
Glycosylation, congenital disorders of, prevalence and pathogenesis, 329
G_{M2} gangliosidoses, locus-specific databases and, 319
***GM2A* gene,** locus-specific databases in G_{M2} gangliosidoses and, 319

H63D mutation, HFE genotypes contribution to iron overload disease and, 271
Health care
CFTR gene and cystic fibrosis interactivity, 124
family practice, family history-taking, genetic screening implications, 180
Health care workers, genetics education and, 226
Health insurance, genetic discrimination by, patient fear of, legal protections and, 214
Health professionals, genetics education and, 226
Hearing screening, universal newborn, ACMG policy statement, 149
Hemochromatosis, HFE genotypes contribution to, 271
Heterogeneity, genetic, late-infantile neuronal ceroid lipofuscinosis, heterogeneity of, 312
Heterotaxy, associated conditions and prevalence in newborns, 157
***HEXA* gene,** locus-specific databases in G_{M2} gangliosidoses and, 319
***HEXB* gene,** locus-specific databases in G_{M2} gangliosidoses and, 319
HFE genotypes, iron overload disease and, 271
Human Genome Project
ethical implications of (commentary), 193
genetic testing validation and (editorial), 155
Hydroxymethylbilane synthase gene, mutations in, acute intermittent porphyria and, 290

In Memoriam, Haun, R. L., 204
Informed consent, medical photographs, ACMG policy statement, 353
Internet
genetics resources on, 296
genetics resources on (letter), 351
Iron overload disease, HFE genotypes contribution to, 271
Isomerism, heterotaxy and, prevalence in newborns, 157

Laterality defects, heterotaxy and, prevalence in newborns, 157
Legal issues
expert witness testimony in medical genetics, ACMG guidelines, 367
genetic discrimination by health insurers, patient fear of, 214
Letters to the Editor, 203, 300, 350
Locus-specific databases, G_{M2} gangliosidoses, 319

Magnetic resonance imaging, Marfan syndrome, dural ectasia in, 173
Mammography, after negative *BRCA1* mutation test result, 307
Marfan syndrome
dural ectasia in, MR and CT findings and criteria, 173
dural ectasia influence in, Berlin vs. Ghent diagnostic criteria, 278
Mental retardation, women with abnormal X chromosome and, 136
Metabolic evaluation, fatty acid transport and mitochondrial oxidation disorders, 338
Metabolism, inborn errors of, molecular diagnosis and, 345
Mitochondrial oxidation disorder, metabolic evaluation, 338
Molecular diagnosis, inborn errors of metabolism and, 345
Muscular dystrophy, limb-girdle, Paget disease of bone and, clinical and molecular studies in family with, 232
Mutation analysis, late-infantile neuronal ceroid lipofuscinosis, heterogeneity of, 312
Mutation pattern, fragile X syndrome, similarity in siblings, comparison with unrelated patients, 242

Neonatal screening
fatty acid transport and mitochondrial oxidation disorders, 338
hearing screening, universal, ACMG policy statement, 149
tandem mass spectrometry in, ACMG/ASHG statement, 267
Neonate, heterotaxy, associated conditions and prevalence, 157
Neural tube defects, folic acid prevention of, college women's awareness and consumption of, 209
Neuronal ceroid lipofuscinosis, late-infantile, heterogeneity of, 312

Obesity, interstitial duplications and, 131
Optic atrophy, clinical heterogeneity of, 283
Osteoporosis, familial risk profile for, 222

Paget disease of bone, limb-girdle muscular dystrophy and, clinical and molecular studies in family with, 232
Patient photographs, informed consent for, ACMG policy statement, 353
Pediatrics, chorionic villus sampling, malformations in children exposed to (letter), 300
Pervasive developmental disorder, interstitial duplications and, 131
Polysplenia, heterotaxy and, prevalence in newborns, 157
Porphobilinogen deaminase, hydroxymethylbilane synthase gene mutations, acute intermittent porphyria and, 290
Porphyria, acute intermittent, mutations in hydroxymethylbilane synthase gene, 290
Prader-Willi/Angelman syndrome
interstitial duplications, phenotype correlations for, 131
phenotype for (letter), 301
Pregnancy, neural tube defect, folic acid for prevention, college women's awareness and consumption of, 209
Primary care, family history-taking in family practice, 180
Public health, public communication of findings in genetics (commentary), 198

Research
genetic testing, population-based registry use in validation of, 186
medical photographs, informed consent for, ACMG policy statement, 353

Self-injurious behavior, interstitial duplications and, 131
Sequence variations, interpretation of, ACMG recommendations for standards for, 302

Sex testing, genetic, female Olympic athletes, 249
Sexual differentiation, genetic, female Olympic athletes, 249
Situs ambiguous, heterotaxy and, prevalence in newborns, 157
Situs inversus, heterotaxy and, prevalence in newborns, 157
Spectrometry, tandem mass, in neonatal screening, ACMG/ASHG statement, 267
Speech delays, developmental, interstitial duplications and, 131
Spinal deformity, Marfan syndrome, dural ectasia in, MR and CT findings and criteria, 173
Strabismus, interstitial duplications and, 131
Stroke, genetic testing validation and (editorial), 155

t

Telemedicine, impact on medical practice (letter), 351

v

Verbal disabilities, verbal dyspraxia, in galactosemia, outcomes analysis, 142

w

World Wide Web: *see* Internet

x

X chromosome, abnormal, X inactivation pattern in women with, 136